GlassScriptPhysician profile
Samantha Claybern
NPI 1639729312
$6,846.66
in general payments reported to CMS, 2019-2025
32 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $67.78 · 2022: $1,644 · 2023: $2,165 · 2024: $1,607 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $705.77 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $606.22 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $592.76 | 2021-2025 | Trintellix |
| Glaxosmithkline, LLC. | $580.20 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $464.02 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $365.07 | 2022-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $328.26 | 2022-2025 | |
| Exact Sciences Corporation | $274.89 | 2023-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $248.42 | 2023-2025 | Wellbutrin, Aplenzin |
| Bayer Healthcare Pharmaceuticals INC. | $234.68 | 2022-2025 | |
| Axsome Therapeutics, INC. | $183.45 | 2023-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $178.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $142.51 | 2022-2024 | |
| Esperion Therapeutics, INC. | $133.69 | 2022-2025 | Nexletol |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.90 | 2022-2023 | Jardiance, Synjardy, Tradjenta |
| Phathom Pharmaceuticals, INC. | $123.49 | 2024-2025 | Voquezna |
| Medtronic, INC. | $100.62 | 2025 | Minimed 780g |
| Verona Pharma, INC. | $73.03 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $50.80 | 2022-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $47.32 | 2022 | |
| Idorsia Pharmaceuticals US INC | $45.52 | 2022-2024 | Quviviq |
| Nevro Corp. | $38.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.83 | 2023-2025 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $32.35 | 2021-2023 | |
| Abbott Laboratories | $26.48 | 2022-2023 | Freestyle Libre |
| Qiagen, LLC | $19.82 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.99 | 2022 | |
| Azurity Pharmaceuticals, INC. | $18.37 | 2024 | Edarbi |
| Eisai INC. | $16.04 | 2022 | |
| Philips North America LLC | $15.66 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Astellas Pharma US INC | $13.61 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Claybern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.